XCancer

A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naive Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors

Description:

Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive)

Sponsor:

RadioMedix

Phase:

Phase 2

Contacts:

Ebrahim S Delpassand, MD

edelpassand@radiomedix.com

7134999733

Government Study Link:

NCT05153772 - Click here to see study on

ClinicalTrials.gov